Product Description
For the Treatment of Subjects With Knee Osteoarthritis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00486434)
Mechanisms of Action: Calcitonin Receptor Stimulant
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nordic Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Osteoarthritis, Knee
Phase 2: Osteoarthritis
Phase 1: Osteoporosis, Postmenopausal|Osteoarthritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
OA 2 Study | P3 |
Terminated |
Osteoarthritis, Knee |
2011-05-01 |
|
CSMC021A2112 | P1 |
Completed |
Osteoporosis, Postmenopausal |
None |
|
CSMC021C2102 | P1 |
Completed |
Osteoarthritis |
None |
|
CSMC021A2111 | P1 |
Completed |
Osteoporosis, Postmenopausal |
None |